We are building an experienced, thoughtful Leadership Team bringing together scientific & clinical expertise, comprehensive industry experience and a track record of success.
Chris Nowers
Chief Executive Officer
Chris Nowers is a senior global biopharma executive with significant experience in the areas of cell therapy and immuno-oncology. He joined ONK Therapeutics as CEO in October 2020.
Michael O’Dwyer MD
Founder and Chief Scientific Officer
Michael O’Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments. He is a Founder of ONK Therapeutics and has been the company’s CSO since its inception in 2015.
George Schlich
Patent Attorney
George Schlich is a UK and European Patent Attorney, a founding director of ONK Therapeutics and has been responsible from the start for the IP portfolio.
Chris Nowers
Chief Executive Officer
Chris Nowers is a senior global biopharma executive with significant experience in the areas of cell therapy and immuno-oncology. He joined ONK Therapeutics as CEO in October 2020.
Michael O’Dwyer MD
Founder and Chief Scientific Officer
Michael O’Dwyer is an experienced Clinician Scientist with a strong track record in clinical and translational research in blood cancers and has been involved in the clinical drug development of many ground-breaking treatments. He is a Founder of ONK Therapeutics and has been the company’s CSO since its inception in 2015.
Rohit Duggal
Head of R&D, USA
Rohit Duggal is an experienced industry-research leader who specializes in establishing and advancing cell therapy and immuno-oncology platforms for product development. He joined ONK therapeutics as Head of R&D, USA in October 2020.
George Schlich
Patent Attorney
George Schlich is a UK and European Patent Attorney, a founding director of ONK Therapeutics and has been responsible from the start for the IP portfolio.
